SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on June 1, 2018. The registrant is a Delaware corporation headquartered in San Diego, California. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing discloses the distribution of a corporate presentation (Exhibit 99.1) used by management at investor conferences.
Guidance, Outlook, and Risks
- Regulation FD Disclosure: The company attached a June 2018 corporate presentation as Exhibit 99.1 under Item 7.01.
- Legal Status of Information: The information contained in the presentation is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Outlook: Specific guidance or forward-looking statements are contained within the attached presentation, which is not included in the text of this filing.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Corporate Presentation dated June 2018) for any forward-looking statements or strategic updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation is not legally incorporated by reference into other SEC filings unless specifically cited.
- Note the discrepancy in the request metadata: The filing is for Imprimis Pharmaceuticals, Inc., not "Harrow, Inc."